Diabetic Retinopathy Market to Grow at 6% CAGR to 2019 - Globally Analysis Report

Diabetic retinopathy is a disorder of the eye that damages the blood vessels of the retina. The retina is the light-sensitive inner surface of the eye on which images are formed. Long-term diabetes affects the retina as high blood glucose levels can damage the tiny blood vessels in the retina. Diabetic retinopathy is broadly classified into non-proliferative diabetic retinopathy and proliferative retinopathy. Treatment for diabetic retinopathy depends on the stage of the disease and is directed toward slowing down or stopping the progression of the disease. Laser surgery, injection of corticosteroids or anti-VEGF drugs into the eye, and vitrectomy are some of the available treatments. One feature of diabetic retinopathy is diabetic macular edema. This is a serious medical condition involving leakage of fluid from the minute, delicate, and previously injured blood vessels located at the back of the eye, which then collects in the macula. This results in inflammation of tissue and blurry vision.

The analysts forecast global diabetic retinopathy market to grow at a CAGR of 6.89% over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the global diabetic retinopathy market for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of prescribed as well as off-label drugs available in the market.

The report also presents the vendor landscape and a corresponding detailed analysis of the four major vendors in the market. In addition, it discusses the major drivers that influence the growth and the challenges faced by the vendors and the market at large, as well as the key trends that contribute to the growth the market.

The report, Global Diabetic Retinopathy Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the global diabetic retinopathy market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Bayer
  • F. Hoffmann-La Roche
  • Novartis
  • Regeneron Pharmaceuticals

Purchase a copy of the report at

Other Prominent Vendors

  • Actavis
  • Alimera Sciences
  • Ampio Pharmaceuticals
  • Antisense Therapeutics
  • BCN Peptides
  • Boehringer Ingelheim
  • Glycadia
  • iCo Therapeutics
  • Isis Pharmaceuticals
  • Kowa Group
  • Lpath
  • Numoda Capital
  • Ohr Pharmaceutical
  • OPKO Health
  • Parexel International
  • Promedior
  • pSivida
  • Quark Pharmaceuticals
  • R-Tech Ueno
  • Sirnaomics
  • ThromboGenics

Market Driver

  • Growth in patient population

Market Challenge

  • Availability of effective surgical treatments

Market Trend

  • Launch of novel agents

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

For more Information on the report, inquire

About US:   ( is an online market research store for research reports on multiple industries. These reports provide market analysis, trends and opportunities and forecast about industries that helps to make a right decision for the business.